Cytokinetics(US:CYTK) Newsfile·2025-11-16 15:35Core Viewpoint - Rosen Law Firm is encouraging investors of Cytokinetics, Inc. to secure legal counsel before the November 17, 2025 deadline related to a securities class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Cytokinetics made false or misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process, leading to investor damages when the true details became public [5].